The sALCL, primary cutaneous ALCL, and BIA-ALCL had similar characteristics, involving constitutive activation of the STAT3 pathway, PD-L1/PD-1 immune-checkpoint expression, PD-L1 gene amplification, and TP53 deficiency (36). The gene discussed is STAT3; the disease is anaplastic large cell lymphoma.